Immutep Ltd has released a press release.
Encouraging Phase II TACTI-002 data reported at SITC 2020
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep Announces Australian Patent Grant for IMP701
- Immutep enters into a Licence & Collaboration with LabCorp
- 2020 AGM Presentation
- COVID-19 phase 2 investigator initiated trial commences
- Immutep granted European patent for IMP761
Later from Immutep
- Pause in Trading
- Proposed issue of Securities - IMM
- Immuteps partner EOC pharma to start Ph II trial in MBC
- Immutep Upscales Efti Manufacturing
- Immutep granted US patent for eftilagimod alpha with a PD-1
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep